Get Live Data

REMINDER: Our user survey closes on Friday, please submit your responses here. 

Less Ads, More Data, More Tools Register for FREE
Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPO
Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPOView Video
Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plant
Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plantView Video

Latest Share Chat

  2. Share Prices
  3. VEC.L Share Price
  4. VEC.L Share News

Pin to quick picksVEC.L Share News (VEC)

VEC.L Information
  • There is currently no data for VEC

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

19 May 2014 05:30

UK Earnings, Trading Statements Calendar - Week Ahead

UK Earnings, Trading Statements Calendar 
Read more
16 May 2014 15:43

UK Earnings, Trading Statements Calendar - Week Ahead

UK Earnings, Trading Statements Calendar 
Read more
16 May 2014 05:36

REPEAT: UK Earnings, Trading Statements Calendar - Week Ahead

UK Earnings, Trading Statements Calendar 
Read more
16 May 2014 05:09

UK Earnings, Trading Statements Calendar - Week Ahead

UK Earnings, Trading Statements Calendar 
Read more
15 May 2014 15:23

UK Earnings, Trading Statements Calendar - Week Ahead

UK Earnings, Trading Statements Calendar 
Read more
15 May 2014 05:30

UK Earnings, Trading Statements Calendar - Week Ahead

UK Earnings, Trading Statements Calendar 
Read more
14 May 2014 15:15

UK Earnings, Trading Statements Calendar - Week Ahead

UK Earnings, Trading Statements Calendar 
Read more
30 Apr 2014 14:18

Vectura Confirms Novartis Data Showing Utilibro Superior COPD Drug

LONDON (Alliance News) - Vectura Group PLC Wednesday confirmed data from Novartis AG regarding positive results from a Phase III study comparing its Utilbro Breezhaler with GlaxoSmithKline PLC's Seretide Accuhaler for the treatment of chronic obstructive pulmonary disease. In the test Ultib

Read more
29 Apr 2014 11:16

Vectura Triggers Final Milestone Payment Under 2010 Glaxo Licensing Deal

LONDON (Alliance News) - Respiratory treatment development company Vectura Group PLC Tuesday said it has triggered a GBP2 million milestone payment from GlaxoSmithKline PLC, a day after the drugs giant launched its chronic obstructive pulmonary disease treatment Anoro Ellipta in the US. Gla

Read more
11 Apr 2014 14:43

Vectura Group to begin European study for asthma treatment

Vectura Group will begin a study in Europe later this calendar year for Favolir, its investigational product for severe, uncontrolled asthma. This group said the decision underlines the company's planned strategy for a broad European development programme for Favolir, rather than a country-specific

Read more
11 Apr 2014 07:59

Vectura To Begin European Study For Asthma Treatment Favolir In 2014

LONDON (Alliance News) - Vectura Group PLC said Friday that it will begin a "pivotal" study in Europe later in 2014 for its product Favolir in the treatment of severe, uncontrolled asthma. The company said that the study is part of its strategy for a broad development programme across Europ

Read more
9 Apr 2014 09:09

Wednesday broker round-up UPDATE

Aberdeen Asset Management: RBC Capital moves target price from 485p to 495p and maintains an outperform rating. African Barrick Gold: Deutsche Bank upgrades to buy with a target price of 310p. African Minerals: Investec reduces target price from 241p to 198p and leaves its buy recommendation uncha

Read more
25 Mar 2014 13:40

Vectura Triggers USD3 Million Milestone Payment For VR315 Development

LONDON (Alliance News) - Vectura Group PLC said Tuesday that it had triggered a USD3 million development milestone payment through the development of its VR315 product in the US with a pharmaceutical company. Vectura did not name the pharmaceutical company. Vecture is eligible to rece

Read more
20 Mar 2014 10:16

UK BROKER RATINGS: Morgan Stanley Raises SSE To Overweight

LONDON (Alliance News) - The following UK shares received analyst recommendations Thursday morning:
----------
FTSE 100
----------
UBS CUTS SMITHS GROUP PRICE TARGET TO 1220 (1340) PENCE - 'SELL'
----------
JPMORGAN CUTS SMITHS GROUP PRICE TARGET

Read more
20 Mar 2014 09:19

Thursday broker round-up UPDATE

Antofagasta: Deutsche Bank cuts target price from 770p to 735p and downgrades to sell. Investec cuts target price from 753p to 726p keeping its sell recommendation. Ashmore Group: HSBC Holdings lowers target price from 410p to 400p retaining its overweight rating. Avacta Group: Numis shifts target

Read more
222324252627282930

Quickpicks are a member only feature

Login to your account